More than 60 researchers ask Congress to support innovation
Earlier this month, 62 researchers from our member companies came to Washington, DC to meet with congressional offices during our annual fly-in event.
Earlier this month, 62 researchers from our member companies came to Washington, DC to meet with congressional offices during our annual fly-in event.
Earlier this month, 62 researchers from our member companies came to Washington, DC to meet with congressional offices during our annual fly-in event. This year included a record-breaking number of meetings — 145 over the course of the day.
I had the privilege to meet the researchers and hear about how they work every day on behalf of patients. My hope is that in sharing their stories with members of Congress, our researchers were able to demonstrate our industry’s continued commitment to finding cures and the importance of policies that support innovation.
The researchers who work at our member companies know firsthand the complexity of the research and development process and the incredible uphill battle that is required to develop new medicines. Because of this experience and expertise, the researchers shared with policymakers the negative impact harmful policies, such as the pill penalty in the Inflation Reduction Act, would have on the development of new treatments and cures for patients.
After three years of virtual fly-ins, we were grateful our researchers could once again be in person on Capitol Hill. Thanks to all who made the trip to DC to share their story with policymakers.